News

Article

Alumis and Acelyrin file a definitive proxy statement for proposed merger

Key Takeaways

  • Alumis and Acelyrin plan a merger, with stockholder meetings set for May 13, 2025, and voting rights based on April 1, 2025, records.
  • Acelyrin stockholders will receive 0.4274 shares of Alumis stock per share owned, resulting in a 55% ownership for Alumis stockholders post-merger.
SHOW MORE

Each company will hold a respective special meeting of stockholders to vote on the approval of the merger.

(Image Credit: AdobeStock/Andrii Yalanskyi)

(Image Credit: AdobeStock/Andrii Yalanskyi)

Alumis and Acelyrin have filed a definitive proxy statement/prospectus with the US Securities and Exchange Commission for the proposed merger of the companies.

According to a joint statement from the company, each company will hold a respective special meeting of stockholders on Tuesday, May 13, 2025. Stockholders of record as of the close of business on April 1, 2025, will be entitled to vote at the respective special meetings of stockholders. Acelyrin stockholders will receive 0.4274 shares of Alumis common stock for each share of Acelyrin common stock owned. Upon close, Alumis stockholders will own ~55% of the combined company, and Acelyrin stockholders will own ~45% of the combined company.

The companies stated that by combining assets, resources, and talent, including members of Acelyrin’s lonigutamab program, the combined company will be well positioned to maximize the value of its pipeline. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease.

Pending approval, the companies stated that the merging of the two companies will “create a late-stage clinical biopharma company dedicated to innovating, developing, and commercializing transformative therapies for immune-mediated diseases.”

The transaction is expected to close in Q2 of 2025, subject to approval by the stockholders of both companies and satisfaction of other customary closing conditions.

References:
  1. Alumis and ACELYRIN file joint definitive proxy statement for proposed merger. Published April 4, 2025. Accessed April 7, 2025. https://investors.alumis.com/news-releases/news-release-details/alumis-and-acelyrin-file-joint-definitive-proxy-statement

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.